ES2329689T3 - Composiciones y procedimientos para el diagnostico de tumores. - Google Patents

Composiciones y procedimientos para el diagnostico de tumores. Download PDF

Info

Publication number
ES2329689T3
ES2329689T3 ES05019847T ES05019847T ES2329689T3 ES 2329689 T3 ES2329689 T3 ES 2329689T3 ES 05019847 T ES05019847 T ES 05019847T ES 05019847 T ES05019847 T ES 05019847T ES 2329689 T3 ES2329689 T3 ES 2329689T3
Authority
ES
Spain
Prior art keywords
polypeptides
present
treatment
diagnosis
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05019847T
Other languages
English (en)
Inventor
David Botstein
Audrey Goddard
Austin L Gurney
Margaret Ann Roy
Colin K Watanabe
William I Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/en
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2329689T3 publication Critical patent/ES2329689T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01133—Xylosylprotein 4-beta-galactosyltransferase (2.4.1.133)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)

Abstract

Anticuerpo aislado que se une a un polipéptido PRO3567, para su uso en un procedimiento de diagnóstico de cáncer de colon practicado en el cuerpo humano o animal, en el que dicho PRO3567 es una secuencia de aminoácido a) que tiene al menos el 99% de identidad en la secuencia de aminoácidos mostrada en la Figura 2 (SEC ID Nº: 27); b) que da una valoración al menos el 99% de positivos cuando se compara con una secuencia de aminoácidos seleccionada mostrada en la Figura 2 (SEC ID Nº: 27); c) que tiene al menos el 99% de identidad en la secuencia de aminoácidos con una secuencia de aminoácidos codificada por la secuencia codificante de longitud completa del ADN depositado con el número de entrada en la ATCC 203662; d) que tiene al menos el 99% de identidad en la secuencia de aminoácidos con el polipéptido mostrado en la Figura 2 (SEC ID Nº: 27), que carece de su péptido señal asociado; e) que tiene al menos el 99% de identidad en la secuencia de aminoácidos con un dominio extracelular del polipéptido mostrado en la Figura 2 (SEC ID Nº: 27), con su péptido señal asociado; o f) que tiene al menos el 99% de identidad en la secuencia de aminoácidos con un dominio extracelular del polipéptido mostrado en la Figura 2 (SEC ID Nº: 27), que carece de su péptido señal asociado.
ES05019847T 1999-03-08 1999-12-02 Composiciones y procedimientos para el diagnostico de tumores. Expired - Lifetime ES2329689T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
PCT/US1999/020111 WO2000012708A2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
US16250699P 1999-10-29 1999-10-29
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization

Publications (1)

Publication Number Publication Date
ES2329689T3 true ES2329689T3 (es) 2009-11-30

Family

ID=29215742

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05019849T Expired - Lifetime ES2324876T3 (es) 1999-03-08 1999-12-02 Composiciones y metodos para el diagnostico de tumores.
ES05019847T Expired - Lifetime ES2329689T3 (es) 1999-03-08 1999-12-02 Composiciones y procedimientos para el diagnostico de tumores.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES05019849T Expired - Lifetime ES2324876T3 (es) 1999-03-08 1999-12-02 Composiciones y metodos para el diagnostico de tumores.

Country Status (9)

Country Link
EP (6) EP1159422A1 (es)
JP (7) JP2003525585A (es)
KR (5) KR100543857B1 (es)
AT (2) ATE439431T1 (es)
AU (4) AU773055C (es)
CA (1) CA2367334A1 (es)
DE (2) DE69941273D1 (es)
ES (2) ES2324876T3 (es)
WO (1) WO2000053750A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914130B2 (en) * 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1140120A4 (en) * 1998-12-23 2003-05-07 Human Genome Sciences Inc BRAINIAC-5 HUMANS
AU1342501A (en) * 1999-10-29 2001-05-14 Human Genome Sciences, Inc. 32 human secreted proteins
WO2001066720A1 (fr) * 2000-03-10 2001-09-13 Toshio Kitamura Genes de souris d'origine adipocyte
AU2001271622A1 (en) * 2000-06-30 2002-01-14 Millennium Pharmaceuticals, Inc. 32626, a human udp-glycosyltransferase and uses thereof
JP2004516013A (ja) * 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
WO2002066654A2 (en) * 2001-02-16 2002-08-29 Incyte Genomics, Inc. Drug metabolizing enzymes
GB0110273D0 (en) * 2001-04-26 2001-06-20 Inpharmatica Ltd Novel proteins
JP2004147542A (ja) * 2002-10-30 2004-05-27 National Institute Of Advanced Industrial & Technology 糖転移酵素及びそれをコードする核酸、並びに該核酸を用いた癌組織の検出方法
EP1863340A2 (en) * 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP2009131151A (ja) * 2006-02-28 2009-06-18 Osaka Univ ＰＩＬＲαと結合するポリペプチド、およびそれをコードするポリヌクレオチド、並びにその利用
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
CN104342444B (zh) * 2013-07-23 2017-11-17 四川大学华西医院 一种重组trail蛋白及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000603A1 (en) * 1992-06-26 1994-01-06 The Trustees Of Princeton University Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes
US5976790A (en) * 1992-03-04 1999-11-02 The Regents Of The University Of California Comparative Genomic Hybridization (CGH)
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
WO2000036102A2 (en) * 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1027430A4 (en) * 1997-07-16 2001-09-19 Human Genome Sciences SERIES OF 64 HUMAN SECRETED PROTEINS
EP1037977B1 (en) * 1997-12-17 2009-08-26 Serono Genetics Institute S.A. EXTENDED cDNAs FOR SECRETED PROTEINS
JP2002508167A (ja) * 1997-12-18 2002-03-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １１０個のヒト分泌タンパク質
CA2314379A1 (en) * 1997-12-18 1999-06-24 Human Genome Sciences, Inc. Human dendriac and brainiac-3
DK1490386T3 (da) * 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
WO1999061471A2 (en) * 1998-05-29 1999-12-02 Incyte Pharmaceuticals, Inc. Human transmembrane proteins
CA2333917A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
AU1181900A (en) * 1998-11-17 2000-06-05 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins
EP1140120A4 (en) * 1998-12-23 2003-05-07 Human Genome Sciences Inc BRAINIAC-5 HUMANS
EP1147182A2 (en) * 1999-01-12 2001-10-24 ZymoGenetics, Inc. Human beta-1,3-galactosyltransferase homolog, znssp6
ATE300553T1 (de) * 1999-02-10 2005-08-15 Genentech Inc Sekretiertes polypeptide und dafür kodierende nukleinsäuren
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
AU5706000A (en) * 1999-06-29 2001-01-31 Kyowa Hakko Kogyo Co. Ltd. Useful polypeptide
EP1194549A2 (en) * 1999-07-02 2002-04-10 Chiron Corporation Human genes and gene expression products
JP2002017375A (ja) * 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 全長ｃＤＮＡ合成用プライマー、およびその用途
EP1130094A3 (en) * 1999-07-08 2001-11-21 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
WO2001012659A2 (en) * 1999-08-18 2001-02-22 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Human dna sequences
WO2001018046A2 (en) * 1999-09-10 2001-03-15 Corixa Corporation Ovarian tumor sequences and methods of use therefor
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides

Also Published As

Publication number Publication date
EP1642967A3 (en) 2006-07-26
KR100473551B1 (en) 2005-03-14
AU2004201760A1 (en) 2004-05-20
ATE427319T1 (de) 2009-04-15
JP2003274979A (ja) 2003-09-30
EP1642906A3 (en) 2006-07-26
EP1642907B1 (en) 2009-04-01
AU2004201769B2 (en) 2007-07-19
EP1159422A1 (en) 2001-12-05
AU773055C (en) 2004-12-02
CA2367334A1 (en) 2000-09-14
KR100566839B1 (ko) 2006-04-03
JP2009000114A (ja) 2009-01-08
ATE439431T1 (de) 2009-08-15
ES2324876T3 (es) 2009-08-18
EP1642968A3 (en) 2006-06-21
AU2004201759B2 (en) 2007-07-19
KR100543857B1 (ko) 2006-01-23
EP1642967A2 (en) 2006-04-05
DE69941273D1 (de) 2009-09-24
KR20040073588A (ko) 2004-08-19
EP1642907A2 (en) 2006-04-05
JP2003274980A (ja) 2003-09-30
AU3107700A (en) 2000-09-28
KR100473550B1 (en) 2005-03-15
AU2004201759A1 (en) 2004-05-20
EP1642907A3 (en) 2006-06-21
EP1634892A2 (en) 2006-03-15
JP2003525585A (ja) 2003-09-02
AU2004201769A1 (en) 2004-05-27
JP2003274977A (ja) 2003-09-30
KR20040077790A (ko) 2004-09-06
EP1634892A3 (en) 2006-06-21
JP2003274978A (ja) 2003-09-30
WO2000053750A1 (en) 2000-09-14
KR20020008123A (ko) 2002-01-29
JP2009039097A (ja) 2009-02-26
EP1642968A2 (en) 2006-04-05
KR100517848B1 (en) 2005-09-30
AU773055B2 (en) 2004-05-13
DE69940681D1 (de) 2009-05-14
EP1642968B1 (en) 2009-08-12
AU2004201760B2 (en) 2007-07-19
KR20040088077A (ko) 2004-10-15
KR20050004773A (ko) 2005-01-12
EP1642906A2 (en) 2006-04-05

Similar Documents

Publication Publication Date Title
DK1632499T3 (da) Gensekvenser amplificeret i tumorer og diagnistiske anvendelser deraf
WO2000053755A3 (en) Compositions and methods for the treatment of tumor
ATE397063T1 (de) Fibroblasten-wachstumsfaktor-19
DE60042799D1 (de) Methoden zur Diagnose von Tumoren
ES2329689T3 (es) Composiciones y procedimientos para el diagnostico de tumores.
WO1999014327A3 (en) Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
WO2003032813A3 (en) Methods for the treatment of carcinoma
DE60045247D1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
WO2000037640A3 (en) Compositions and methods for the treatment of tumor
WO2004075835A3 (en) Methods for the treatment of renal cell carcinoma
WO2000015666A3 (en) Compositions and methods for the treatment of tumors